UDP Glucuronosyltransferase 1 Family, Polypeptide A1 (UGT1A1), Recombinant Prot

UGT1; GNT1; UGT1A; UDPGT; HUG-BR1; UGT1-1; Bilirubin-specific UDPGT isozyme 1; UDP-glucuronosyltransferase 1-1

For Research Use Only. Not for use in diagnostic procedures.

E Coli

> 95%

Freeze-dried powder

Manufactured in an ISO 9001:2008 and ISO 13485:2003 Certified Laboratory.

Manufactured in a lab with traceable raw materials. Bulk orders can typically be prepared to the customer’s specifications, please inquire.

Small volumes of UGT1A1 recombinant protein vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.

Enzyme & Kinase

Positive Control, Immunogen, SDS-PAGE, Western Blot (WB)

Predicted Molecular Weight: 32.0kDa

UDP glucuronosyltransferase family 1 member A1

UDP-glucuronosyltransferase 1-1

UDP-glucuronosyltransferase 1-1

GNT1; UGT1; UDPGT 1-1; UGT1*1; UGT1-01; UGT1.1; hUG-BR1; UGT-1A; UGT1A  [Similar Products]

This gene encodes a UDP-glucuronosyltransferase, an enzyme of the glucuronidation pathway that transforms small lipophilic molecules, such as steroids, bilirubin, hormones, and drugs, into water-soluble, excretable metabolites. This gene is part of a complex locus that encodes several UDP-glucuronosyltransferases. The locus includes thirteen unique alternate first exons followed by four common exons. Four of the alternate first exons are considered pseudogenes. Each of the remaining nine 5' exons may be spliced to the four common exons, resulting in nine proteins with different N-termini and identical C-termini. Each first exon encodes the substrate , and is regulated by its own promoter. The preferred substrate of this enzyme is bilirubin, although it also has moderate activity with simple phenols, flavones, and C18 steroids. Mutations in this gene result in Crigler-Najjar syndromes types I and II and in Gilbert syndrome. [provided by RefSeq, Jul 2008]

UGT1A1: UDPGT is of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds. This isoform glucuronidates bilirubin IX- alpha to form both the IX-alpha-C8 and IX-alpha-C12 monoconjugates and diconjugate. Is also able to catalyze the glucuronidation of 17beta-estradiol, 17alpha-ethinylestradiol, 1-hydroxypyrene, 4- methylumbelliferone, 1-naphthol, paranitrophenol, scopoletin, and umbelliferone. Part a large chaperone multiprotein complex comprising DNAJB11, HSP90B1, HSPA5, HYOU, PDIA2, PDIA4, PDIA6, PPIB, SDF2L1, UGT1A1 and very small amounts of ERP29, but not, or at very low levels, CALR nor CANX. Expressed in liver. Not expressed in skin or kidney. Belongs to the UDP-glycosyltransferase family. 1 isoforms of the human protein are produced by alternative splicing.

Protein type: Carbohydrate Metabolism - ascorbate and aldarate; Carbohydrate Metabolism - pentose and glucuronate interconversions; Carbohydrate Metabolism - starch and sucrose; Cofactor and Vitamin Metabolism - porphyrin and chlorophyll; Cofactor and Vitamin Metabolism - retinol; EC 2.4.1.17; Lipid Metabolism - androgen and estrogen; Membrane protein, integral; Transferase; Xenobiotic Metabolism - drug metabolism - cytochrome P450; Xenobiotic Metabolism - drug metabolism - other enzymes; Xenobiotic Metabolism - metabolism by cytochrome P450

Chromosomal Location of Human Ortholog: 2q37.1

Cellular Component: endoplasmic reticulum; endoplasmic reticulum membrane; integral component of plasma membrane

Molecular Function: enzyme binding; enzyme inhibitor activity; glucuronosyltransferase activity; protein heterodimerization activity; protein homodimerization activity; retinoic acid binding; steroid binding

Biological Process: acute-phase response; bilirubin conjugation; digestion; drug metabolic process; estrogen metabolic process; flavone metabolic process; heme catabolic process; heterocycle metabolic process; liver development; negative regulation of catalytic activity; negative regulation of steroid metabolic process; organ regeneration; response to drug; response to lipopolysaccharide; response to nutrient; response to starvation; retinoic acid metabolic process; steroid metabolic process

Disease: Bilirubin, Serum Level Of, Quantitative Trait Locus 1; Crigler-najjar Syndrome, Type I; Crigler-najjar Syndrome, Type Ii; Gilbert Syndrome; Hyperbilirubinemia, Transient Familial Neonatal

All of MyBioSource's Products are for scientific laboratory research purposes and are not for diagnostic, therapeutics, prophylactic or in vivo use. Through your purchase, you expressly represent and warrant to MyBioSource that you will properly test and use any Products purchased from MyBioSource in accordance with industry standards. MyBioSource and its authorized distributors reserve the right to refuse to process any order where we reasonably believe that the intended use will fall outside of our acceptable guidelines.

While every efforts were made to ensure the accuracy of the information provided in this datasheet, MyBioSource will not be liable for any omissions or errors contained herein. MyBioSource reserves the right to make changes to this datasheet at any time without prior notice.

It is the responsibility of the customer to report product performance issues to MyBioSource within 30 days of receipt of the product. Please visit our Terms & Conditions page for more information.